Athletes With Isolated Non-ischemic LGE With no Underlying Labelled Cardiomyopathy
Conditions
Keywords
Athletes, Late gadolinium enhancement, fibrosis
Brief summary
The prognostic relevance of isolated non-ischemic LGE (i.e. with no underlying labelled cardiomyopathy) is unclear, and current guidelines to not state on the clearance of athlete with this type of findings as regards to competitive or intense sport practice. The principal objective of the study is to evaluate during a five-years follow up, the clinical outcome of athletes with this kind of findings. The secondary objective is the determination of prognostic factors. The management and follow-up of the athletes will be let at the appraisal of each center.
Detailed description
The presence of a scar, assessed by late gadolinium enhancement (LGE) on cardiac resonance imaging (CMR), is associated with a poor prognosis in patients with ischemic heart disease or cardiomyopathy. But the prognostic relevance of isolated non-ischemic LGE (i.e. with no underlying labelled cardiomyopathy) is unclear, and current guidelines do not state on the clearance of athlete with this type of findings as regards to competitive or intense sport practice. The objective of the study is to evaluate the clinical outcome of athletes with isolated non-ischemic LGE with no underlying labelled cardiomyopathy during a five-years follow-up. The secondary objective is the determination of prognostic factors based on the baseline inclusion data: indication of CMR (i.e. symptoms, abnormal ECG, presence and morphology of arrhythmias, abnormal echocardiography); localization and amount of LGE, left and right ventricular geometry and function, characteristics of sport practice (amount, type, competition). The management of the athletes will be let at the appraisal of each centre, as regards to the initial assessment, the follow-up and the medical clearance for competitive sports participation. Nevertheless, due to the absence of consensus, we propose that the patient should at least undergo clinical examination, ECG, echocardiography, cardiopulmonary exercise test (CPET) and holter ECG each year. A CMR should be performed at one and five years.
Interventions
OTHERnon-ischemic scar
non-ischemic LGE with no underlying labelled cardiomyopathy is detected on CMR
Sponsors
Rennes University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Any athlete, aged of more than 15 years, symptomatic or not, * in whom non-ischemic LGE with no underlying labelled cardiomyopathy is detected on CMR. Scare of an acute myocarditis will also be included. Athletes will be defined by a practice of ≥4 hours/week of sport activity and/or competitive sport activity at the time of the assessment which triggered the realization of the 1st CMR.
Exclusion criteria
* Athletes with any unequivocal cardiac disease that might explain the LGE (i.e. hypertrophic cardiomyopathy, ischemic cardiac disease). In case of borderline or doubtful diagnosis the athlete can still be included (for example an athlete with a dilated LV and borderline function, or with borderline wall thickness). * Patients who refuse their participation in the study. * Patients under legal protection or deprived of their liberty.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of a major cardiac event | five years after inclusion | During a follow-up of 5 years, occurrence of a major cardiac event defined by either: death, death of cardiovascular cause; hospitalization for cardiac event; any major arrhythmic event defined by arrhythmic cardiac arrest, sustained ventricular tachycard |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Functional end-point | five years after inclusion | alteration of exercise capacity, defined by a reduction ≥10% of peak VO2, not explained by training changes |
| Morphological end-point | five years after inclusion | Alteration of left ventricular (LV) function defined by a decrease in LVEF as compared to the initial evaluation (≥10%, or occurrence of a new wall motion abnormality assessed the same imaging technic, i.e. echocardiography or CMR) |
| Arrhythmic end-point | five years after inclusion | Occurrence of a non-sustained VT (NSVT), defined as a tachycardia originating in the ventricle \>100 beats/min and lasting ≥3 beats but less than 30 seconds. |
Countries
Australia, Belgium, France, Germany, Luxembourg, United Kingdom
Contacts
Primary ContactKristell KC COAT
Backup ContactDirection de la recherche
Outcome results
None listed